{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:02:10Z","timestamp":1789970530966,"version":"4.0.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Elevated lipoprotein(a) [Lp(a)] and increased platelet count independently predict major adverse cardiovascular events (MACE), yet their interplay and joint value in cardiovascular risk stratification remain incompletely elucidated. We examined their separate and joint associations with incident MACE, with a secondary exploratory analysis of whether preventive benefit from aspirin differs across biomarker-defined subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      We included 250,927 participants free of prior cardiovascular disease (CVD) from the UK Biobank (enrolled 2006\u20132010). Participants were categorized into four groups based on Lp(a) status (elevated: &amp;gt;125\u2005nmol\/L) and platelet count (increased: upper tertile, &amp;gt;273\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L). Multivariable Cox regression was applied to estimate hazard ratios (HRs) for MACE, adjusted for demographic, lifestyle, metabolic and medication-related covariates. Formal tests for additive and multiplicative interactions were performed. Over a median follow-up of 13.4 years, both elevated Lp(a) (HR 1.250; 95% CI 1.118\u20131.325) and increased platelet count (HR 1.056; 95% CI 1.005\u20131.110) were independently associated with higher MACE risk. Participants with concurrent elevation of both biomarkers carried the highest MACE risk (HR 1.391; 95% CI 1.256\u20131.541). Neither additive nor multiplicative interaction reached statistical significance, indicating that the joint effect reflects additive risk accumulation rather than biological synergy. In exploratory subgroup analyses, aspirin use was associated with lower MACE risk only in the double-high subgroup, but not in those with isolated elevated Lp(a).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Concomitant elevation of Lp(a) and platelet count identifies a subgroup of individuals at substantially higher risk for MACE. The observed potential benefit of aspirin in the double-high subgroup is exploratory and warrants further prospective investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1932150","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:52Z","timestamp":1789968952000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Lp(a), platelet count, aspirin and cardiovascular outcome: a prospective cohort analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Xuan","family":"Song","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Third Affiliated Hospital of Soochow University","place":["Changzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Xin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Third Affiliated Hospital of Soochow University","place":["Changzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Third Affiliated Hospital of Soochow University","place":["Changzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Third Affiliated Hospital of Soochow University","place":["Changzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Third Affiliated Hospital of Soochow University","place":["Changzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chan","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Third Affiliated Hospital of Soochow University","place":["Changzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Cardiometabolic Center, State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-pharmtox-031023-100609","article-title":"LP(a): structure, genetics, associated cardiovascular risk, and emerging therapeutics","volume":"64","author":"Tasdighi","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","article-title":"Residual cardiovascular risk: when should we treat it?","volume":"120","author":"Gomez-Delgado","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events","volume":"82","author":"Thomas","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamacardio.2024.1882","article-title":"Lipoprotein(a) and calcific aortic valve stenosis progression: a systematic review and meta-analysis","volume":"9","author":"Arsenault","year":"2024","journal-title":"JAMA Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.jacc.2025.04.013","article-title":"Lipoprotein(a), cholesterol, triglyceride levels, and vulnerable coronary plaques: a PROSPECT II substudy","volume":"85","author":"Erlinge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jacl.2022.10.004","article-title":"Lipoprotein(a) and inflammation- pathophysiological links and clinical implications for cardiovascular disease","volume":"17","author":"Simantiris","year":"2023","journal-title":"J Clin Lipidol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J Lipid Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/01.ATV.10.2.240","article-title":"Lipoprotein(a), fibrin binding, and plasminogen activation","volume":"10","author":"Loscalzo","year":"1990","journal-title":"Arteriosclerosis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1016\/S0021-9258(18)52266-3","article-title":"Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis","volume":"266","author":"Etingin","year":"1991","journal-title":"J Biol Chem"},{"key":"B12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nm0395-256","article-title":"Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis","volume":"1","author":"Palabrica","year":"1995","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1001\/jamacardio.2024.1874","article-title":"Lipoprotein(a) and long-term plaque progression, low-density plaque, and pericoronary inflammation","volume":"9","author":"Nurmohamed","year":"2024","journal-title":"JAMA Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2022.04.004","article-title":"Lipoprotein(a): an underestimated inflammatory mastermind","volume":"349","author":"Dzobo","year":"2022","journal-title":"Atherosclerosis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e14093","DOI":"10.1111\/eci.14093","article-title":"Healthy lifestyle, lipoprotein (a) levels and the risk of coronary artery disease","volume":"54","author":"Tada","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1161\/ATVBAHA.118.311804","article-title":"Genetically determined platelet count and risk of cardiovascular disease","volume":"38","author":"Gill","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.thromres.2016.08.012","article-title":"Platelet count is associated with cardiovascular disease, cancer and mortality: a population-based cohort study","volume":"148","author":"Vinholt","year":"2016","journal-title":"Thromb Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1038\/s41467-025-57938-9","article-title":"The impact of a high fat diet and platelet activation on pre-metastatic niche formation","volume":"16","author":"Hergueta-Redondo","year":"2025","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/nu13020559","article-title":"Mediterranean diet maintained platelet count within a healthy range and decreased thrombocytopenia-related mortality risk: a randomized controlled trial","volume":"13","author":"Hern\u00e1ez","year":"2021","journal-title":"Nutrients"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3324\/haematol.2021.279770","article-title":"Critical role of peroxisome proliferator-activated receptor \u03b1 in promoting platelet hyperreactivity and thrombosis under hyperlipidemia","volume":"107","author":"Li","year":"2022","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J Lipid Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","article-title":"Lipoprotein(a), platelet function and cardiovascular disease","volume":"21","author":"Bhatia","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1160\/TH07-04-0285","article-title":"Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials","volume":"98","author":"Iijima","year":"2007","journal-title":"Thromb Haemostasis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van Der Valk","year":"2016","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.jacc.2024.03.367","article-title":"Association of lipoprotein(a) levels with myocardial infarction in patients with low-attenuation plaque","volume":"83","author":"Yu","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1093\/cvr\/cvad099","article-title":"Single-cell profiling reveals age-associated immunity in atherosclerosis","volume":"119","author":"Smit","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1093\/eurheartj\/ehad361","article-title":"Subclinical atherosclerosis and accelerated epigenetic age mediated by inflammation: a multi-omics study","volume":"44","author":"S\u00e1nchez-Cabo","year":"2023","journal-title":"Eur Heart J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/clinchem\/48.9.1454","article-title":"Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases","volume":"48","author":"Akaike","year":"2002","journal-title":"Clin Chem"},{"key":"B32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.05.003","article-title":"Effect of aspirin on lipoprotein(a) in patients with ischemic stroke","volume":"16","author":"Ranga","year":"2007","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"807925","DOI":"10.3389\/fcvm.2021.807925","article-title":"Benefit and risk of prolonged dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents in patients with elevated lipoprotein(a) concentrations","volume":"8","author":"Cui","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"zwaf547","DOI":"10.1093\/eurjpc\/zwaf547","article-title":"Aspirin use and the risk for cardiovascular disease by lipoprotein(a) levels: a multi-cohort study","author":"Colantonio","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e033562","DOI":"10.1161\/JAHA.123.033562","article-title":"Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): the multi-ethnic study of atherosclerosis","volume":"13","author":"Bhatia","year":"2024","journal-title":"J Am Heart Assoc"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1932150\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:53Z","timestamp":1789968953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1932150\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":36,"alternative-id":["10.3389\/fcvm.2026.1932150"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1932150","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1932150"}}